Small molecule · Inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3K p11 (PIK3CA) · developed by Relay Therapeutics
RLY-5836 is an orally bioavailable, pan-mutant selective inhibitor of the PI3K p110alpha catalytic subunit encoded by PIK3CA. It allosterically binds mutant forms of PIK3CA, preventing mutant-driven activation of the PI3K/Akt/mTOR pathway. It is being studied in PIK3CA-mutated solid tumors and breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05759949 | Phase 1 | PIK3CA Mutation | Completed | RLAY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Breast CancerBreast CancerHER2-negative Breast CancerHormone Receptor Positive TumorMetastatic Breast CancerPIK3CA MutationSolid Tumor, AdultUnresectable Solid Tumor
Updated Nov 1, 2026. Something wrong or missing? Report it on the RLAY page.
See RLAY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RLAY catalysts and pipeline →